Influence of the preparation method on the physicochemical properties of econazole-β-cyclodextrin complexes

  • Ali H. Al-Marzouqi
  • Ayser Solieman
  • Ihsan Shehadi
  • Abdu Adem
Original Article


Econazole (C18H15Cl3N2O) is one of the common antifungal agents whose poor aqueous solubility restricts its use for the treatment of oropharyngeal candidiasis, which is the first symptom of HIV infection. Therefore, the aim of the current study was to investigate the effect of different preparation methods (i.e. kneading, coevaporation, sealed-heating, and supercritical carbon dioxide (SC CO2)) for obtaining solid inclusion complexes between β-cyclodextrin and econazole. The physico-chemical properties of the different products were characterized by differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR) and powder X-ray diffractometry (PXRD). For the complexes prepared by the SC CO2 method, the effects of temperature and pressure have also been investigated and related to the solubility of econazole in SC CO2. Results suggested the validity of the SC CO2 method for preparing solid complexes between cyclodextrins and econazole, avoiding the use of organic solvents and problems of their complete removal. Moreover, temperature played a major role in promoting drug-carrier interactions, whereas pressure had limited effects.


Cyclodextrin Econazole Inclusion complex Supercritical carbon dioxide 



The authors are grateful to the Research Affairs at the United Arab Emirates University for the financial support of this project (contract no. 01-02-7-12/04) and to Ali Dowaidar and Baboucarr Jobe for their assistance with analysis of the samples.


  1. 1.
    Hughes, W.T., Bartley, D.L., Patterson, G.G., Tufenkeji, H.: Ketoconazole and candidiasis: a controlled study. J. Infect. Dis. 147, 1060–1063 (1983)Google Scholar
  2. 2.
    Murray, P.A., Koletar, S.L., Mallegol, I., Wu, J., Moskovitz, B.L.: Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients. Clin. Ther. 19, 471–480 (1997)CrossRefGoogle Scholar
  3. 3.
    Hay, R.J.: Overview of studies of fluconazole in oropharyngeal candidiasis. Rev. Infect. Dis. 12(suppl. 3), S334–S337 (1990)Google Scholar
  4. 4.
    Meunier, F., Aoun, M., Gerard, M.: Therapy of oropharyngeal candidiasis in the immunocompromised host: a randomized double-blind study of fluconazole vs ketoconazole. Rev. Infect. Dis. 12(suppl. 3), S364–S368 (1990)Google Scholar
  5. 5.
    Darouiche, R.O.: Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin. Infect. Dis. 26, 259–274 (1998)CrossRefGoogle Scholar
  6. 6.
    Pons, V., Greenspan, D., Lozada-Nur, F., McPhail, L., Gallant, J.E., Tunkel, A., Johnson, C.C., McCarty, J., Panzer, H., Levenstein, M., Barranco, A., Green, S.: Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin. Infect. Dis. 24, 1204–1207 (1997)CrossRefGoogle Scholar
  7. 7.
    Szejtli, J.: Cyclodextrins in drug formulations: Part II. Pharm. Technol. Int. Aug., 24–38 (1991)Google Scholar
  8. 8.
    Duchene, D., Wouessidjewe, D.: Physicochemical characteristics and pharmaceutical uses of cyclodextrin derivatives, Part II. Pharm. Technol. Aug., 22–30 (1990)Google Scholar
  9. 9.
    Nambu, N., Kikuchi, K., Kikuchi, T., Takahashi, Y., Ueda, H., Nagai, T.: Influence of inclusion of nonsteroidal antiinflammatory drugs with β-cylcodextrin on the irritation to stomach of rats upon oral administration. Chem. Pharm. Bull. 26(12), 3609–3612 (1978)Google Scholar
  10. 10.
    Dhanaraju, M.D., Kumaran, K.S., Baskaran, T., Moorthy, M.S.R.: Enhancement of bioavailability of Griseofulvin by its complexation with β-cyclodextrin. Drug Dev. Ind. Pharm. 24(6), 583–587 (1998)CrossRefGoogle Scholar
  11. 11.
    Hostetler, J.S., Hanson, L.H., Stevens, D.A.: Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob. Agents Chemother. 36(2), 477–480 (1992)Google Scholar
  12. 12.
    Jacobsen, J., Bjerregaard, S., Pedersen, M.: Cyclodextrin inclusion complexes of antimycotics intended to act in the oral cavity-drug supersaturation, toxicity on TR146 cells and release from a delivery system. Eur. J. Pharm. Biopharm. 48(3), 217–224 (1999)CrossRefGoogle Scholar
  13. 13.
    Lee, B., Lee, J.: Enhancement of solubility and dissolution rate of poorly water-soluble Naproxen by complexation with 2-hydroxypropyl-β-cyclodextrin. Arch. Pharm. Res. 18(1), 22–26 (1995)CrossRefGoogle Scholar
  14. 14.
    Lee, S.Y., Chun, I.K.: Design of new parenteral aqueous formulations of fluconazole by the use of modified cyclodextrins. Yakhak Hoechi. 45(4), 357–365 (2001)Google Scholar
  15. 15.
    Mura, P., Adragna, E., Rabasco, A.M., Moyano, J.R., Perez-Martinez, J.I., Arias, M.J., Gines, J.M.: Effect of the host cavity size and the preparation method on the physicochemical properties of Ibuproxam-cyclodextrin systems. Drug Dev. Ind. Pharm. 25(3), 279–287 (1999)CrossRefGoogle Scholar
  16. 16.
    Mura, P., Faucci, M.T., Manderioli, A., Bramanti, G.: Influence of the preparation method on the physicochemical properties of binary systems of econazole with cyclodextrins. Int. J. Pharm. 193(1), 85–95 (1999)CrossRefGoogle Scholar
  17. 17.
    Strickley, R.: Solubilizing excipients in oral and injectable formulations. Pharm. Res. 21, 201–230 (2004)CrossRefGoogle Scholar
  18. 18.
    Loftsson, T., Masson, M., Brewster, M.: Self-association of cyclodextrins and cyclodextrin complexes. J. Pharm. Sci. 93, 1091–1099 (2004)CrossRefGoogle Scholar
  19. 19.
    Peeters, J., Neeskens, P., Tollenaere, J., Remoortere, P.V., Brewstrer, M.E.: Characterization of the interaction of 2-hydroxypropyl-β-cyclodextrin with Itraconazole at pH 2, 4, and 7. J. Pharm. Sci. 91(6), 1414–1422 (2002)CrossRefGoogle Scholar
  20. 20.
    Van Hees, T., Piel, G., Evrard, B., Otte, X., Thunus, L., Delattre, L.: Application of supercritical carbon dioxide for the preparation of a Piroxicam-β-cyclodextrin inclusion compound. Pharm. Res. 16(12), 1864–1870 (1999)CrossRefGoogle Scholar
  21. 21.
    Van Hees, T., Barillaro, V., Piel, G., Bertholet, P., De Hassonville, S., Evrard, B., Delattre, L.: Application of supercritical carbon dioxide for the preparation of drug-cyclodextrin inclusion compounds. J. Incl. Phenom. Macro. 44, 271–274 (2002)CrossRefGoogle Scholar
  22. 22.
    Bandi, N., Wei, W., Roberts, C.B., Kotra, L.P., Kompella, U.B.: Preparation of budesonide–and indomethacin–hydroxypropyl-β-cyclodextrin (HPBCD) complexes using a single-step, organic-solvent-free supercritical fluid process. Eur. J. Pharm. Sci. 23, 159–168 (2004)CrossRefGoogle Scholar
  23. 23.
    Fabing, I., Leboeuf, F., Jung, J., Perrut, M.: Method for making very fine particles consisting of a principle inserted in a host-molecule. Patents FR 2 815 540- WO 0232462- EP 1 330 266, 2000Google Scholar
  24. 24.
    Perrut, M., Jung, J., Leboeuf, F.: Enhancement of dissolution rate of poorly soluble active ingredients by supercritical fluid processes, Part II: preparation of composite particles. Int. J. Pharm. 288, 11–16 (2005)CrossRefGoogle Scholar
  25. 25.
    Rodier, E., Lochard, H., Sauceau, M., Letourneau, J.-J., Freiss, B., Fages, J.: A three step supercritical process to improve the dissolution rate of Eflucimibe. Eur. J. Pharm. Sci. 26, 184–193 (2005)CrossRefGoogle Scholar
  26. 26.
    Al-Marzouqi, A.H., Jobe, B., Dowaidar, A., Maestrelli, F., Mura, P.: Evaluation of supercritical fluid technology as preparative technique of benzocaine-cyclodextrin complexes-Comparison with conventional methods. J. Pharm. Biomed. Anal. 43, 566–574 (2007)CrossRefGoogle Scholar
  27. 27.
    Al-Marzouqi, A.H., Jobe, B., Corti, G., Cirri, M., Mura, P.: Physicochemical characterization of drug-cyclodextrin complexes prepared by supercritical carbon dioxide and by conventional techniques. J. Incl. Phenom. Macro. 57, 223–231 (2007)CrossRefGoogle Scholar
  28. 28.
    Al-Marzouqi, A.H., Shehatta, I., Jobe, B., Dowaidar, A.: Phase solubility and inclusion complex of itraconazole with β-cyclodextrin using supercritical carbon dioxide. J. pharm. Sci. 95(2), 292–304 (2006)CrossRefGoogle Scholar
  29. 29.
    Shehatta, I., Al-Marzouqi, A.H., Jobe, B., Dowaidar, A.: Enhancement of aqueous solubility of itraconazole by complexation with cyclodextrins using supercritical carbon dioxide. Can. J. Chem. 83(10), 1833–1838 (2005)CrossRefGoogle Scholar
  30. 30.
    Hassan, A., Tang, Y., Ayres, J.: Itraconazole formation using supercritical carbon dioxide. Drug Dev. Ind. Pharm. 30(10), 1029–1035 (2004)CrossRefGoogle Scholar
  31. 31.
    Kiran, E., Brennecke, J.: Supercritical Fluid Engineering Science, ACS Symposium Series 514. American Chemical Society, Washington, D.C. (1993)Google Scholar
  32. 32.
    Charoenchaitrakool, M., Dehghani, F., Foster, N.R.: Utilization of supercritical carbon dioxide for complex formation of ibuprofen and methyl-β-cyclodextrin. Int. J. Pharm. 239, 103–112 (2002)CrossRefGoogle Scholar
  33. 33.
    Türk, M., Upper, G., Steurenthaler, M., Hussein, Kh., Wahl, M.A.: Complex formation of ibuprofen and β-cyclodextrin by controlled particle deposition (CPD) using SC-CO2. J. Supercrit. Fluids 39, 435–443 (2007)CrossRefGoogle Scholar
  34. 34.
    Pedersen, M., Edelsten, M., Nielsen, V.F., Scarpellini, A., Skytte, S., Slot, C.: Formation and antimycotic effect of cyclodextrin inclusion complexes of econazole and miconazole. Int. J. Pharm. 90, 247–254 (1993)CrossRefGoogle Scholar
  35. 35.
    Pedersen, M., Bjerregaard, S., Jacobsen, J., Larsen, A.R., Sørensen, A.M.: An econazole β-cyclodextrin inclusion complex: an unusual dissolution rate, supersaturation, and biological efficacy example. Int. J. Pharm. 165, 57–68 (1998)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2007

Authors and Affiliations

  • Ali H. Al-Marzouqi
    • 1
  • Ayser Solieman
    • 1
  • Ihsan Shehadi
    • 2
  • Abdu Adem
    • 3
  1. 1.Department of Chemical & Petroleum EngineeringUAE UniversityAl-AinUAE
  2. 2.Department of ChemistryUAE UniversityAl-AinUAE
  3. 3.Department of Pharmacology and TherapeuticsUAE UniversityAl-AinUAE

Personalised recommendations